The aim of this eSIBDCS-based study is to determine the impact of biological agents on growth in paediatric Crohn’s disease patients with respect to medication and treatment strategy (top-down vs. step-up approach). Furthermore this study aims at determining whether a particular group of individuals would benefit more from biological agents, growth-wise, and what factors influence this growth benefit. The manuscript has been submitted and publication is expected for the end of 2025. Further information: clea.kunz@unil.ch